Market research
0QQ6.LSE Roche Holding AG
LSE GBP Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 281B
- P/E ratio
- 0.23
- Analyst target
- Not available
- Dividend yield
- 2.6%
- Beta
- 0.35
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Not available
- Industry
- Not available
- ISIN
- CH0012032113
- Market cap
- 281B
- P/E ratio
- 0.23
- Analyst target
- Not available
- Dividend yield
- 2.6%
- Beta
- 0.35
About
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0QQ6.LSE discussion.
5 years, 5 months ago
Roche Holding AG is currently in a long term downtrend where the price is trading 0.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, Roche Holding AG gets an overall score of 1/5.